@Article{096504018X15344989701565,
AUTHOR = {Liwei Jia, Dongying Lv, Shuang Zhang, Zhenyue Wang, Bo Zhou},
TITLE = {Astragaloside IV Inhibits the Progression of Non-Small Cell Lung Cancer  Through the Akt/GSK-3β/β-Catenin Pathway},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {4},
PAGES = {503--508},
URL = {http://www.techscience.com/or/v27n4/48564},
ISSN = {1555-3906},
ABSTRACT = {Astragaloside IV (AS-IV) is an active ingredient in Astragalus membranaceus and is involved in various 
biological processes, such as regulating the immune system, and counteracting inflammation and malignancy. 
The aim of this study was to explore the effect of AS-IV on non-small cell lung cancer (NSCLC) cells. Cell 
counting kit (CCK)-8 assay and flow cytometry were performed to investigate cell survival and cell death, and 
Western blotting was performed to assess protein expression. We found that AS-IV inhibited the migration 
and proliferation of NSCLC cells and caused a noticeable increase in cell death. Furthermore, the expression 
of Bax, a marker of cell death, was increased, whereas the expression of Bcl-2, an antiapoptotic protein, was 
reduced. AS-IV also promoted cleavage of caspase-3, another indication of apoptosis. Finally, the Akt/GSK-
3 / -catenin axis was suppressed in response to AS-IV. Taken together, these findings provide evidence that 
AS-IV inhibits NSCLC development via inhibition of the Akt/GSK-3 / -catenin signaling axis. We therefore 
propose that AS-IV represents a promising novel agent for the treatment of NSCLC.},
DOI = {10.3727/096504018X15344989701565}
}